Jubilant Therapeutics to Present at Biotech Showcase 2020 on January 13, 2020

On January 10, 2020 Jubilant Therapeutics Inc., a patient focused bio-pharmaceutical company focused on addressing unmet needs in Oncology and Auto-immune disorders reported that Syed Kazmi, President & CEO of Jubilant Therapeutics will present at Biotech Showcase 2020 (Press release, Jubilant Therapeutics, JAN 10, 2020, View Source [SID1234553004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Monday, January 13, 2020
Time: 3:45 p.m. PST
Location: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco
Track: Franciscan B (Ballroom Level)

To schedule a meeting with Jubilant Therapeutics during the event, please make a request by email at [email protected]

Neptune Provides Corporate Updates and Discusses 2020 Initiatives

On January 10, 2020 Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (Nasdaq: NEPT) (TSX: NEPT), a health and wellness company focused on extraction, purification and formulation of cannabinoids, reported that would like to provide the following corporate updates and outlook ahead of its participation at the Annual ICR Conference in Orlando, Florida being held on January 13-15, 2020, where Neptune’s CEO, Michael Cammarata, will present and meet with investors (Press release, Neptune Technologies et Bioressources inc, JAN 10, 2020, View Source [SID1234553003]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Consumer Brands Initiatives
Several efforts have been deployed internally to accelerate the Company’s growth in the B2C markets. The official launch of the Forest Remedies brand is expected to occur in February 2020, supported by a public relations campaign and a marketing campaign under our partnership with American Media LLC. The launch will consist of hemp-derived wellness products including ingestibles, such as soft gels and oils, topicals and a pet soother. The Forest Remedies brand launch will also include aromatherapy products developed in collaboration with International Flavors & Fragrances Inc. ("IFF"). Neptune will first launch Forest Remedies online and expects the brand to be available at U.S. retailers shortly thereafter. A media event will be held this spring at IFF’s headquarters to celebrate the brand’s debut.

Neptune is also rebranding OCEANO³ to Ocean Remedies, under which the Company’s omega-3 products will be commercialized. Other product launches under the Ocean Remedies brand are expected this year.

Health Canada License Amendments
At our Sherbrooke facility, the expansion of Neptune’s packaging and warehousing capabilities is tracking as planned. Neptune expects to request an amendment to include these packaging and warehousing areas under the Company’s license granted by Health Canada, in the near future. Licensing these additional areas is expected to significantly increase Neptune’s capabilities to provide turnkey solutions to its customers such as formulation, purification, blending, manufacturing and packaging services. Neptune will also seek to add significant warehouse space, which can be kept at sub-zero temperatures and which should improve logistics to store cannabis biomass and finished products.

Neptune is also in the process of applying to receive permission to sell cannabis products from Health Canada. Upon the addition of the authorization to sell cannabis to the conditions of its license, the Company will be able to sell finished products directly to licensed cannabis distributors and retailers, enabling Neptune to position itself closer to the end customer. Neptune initially expects to launch cannabis products in Canada under its Forest Remedies, Ocean Remedies and Neptune brands.

The Company will utilize some of its future capacity which has recently become available, due in part to delays in the ramp-up of the Canadian cannabis market, to produce its own finished products.

Production Update
In light of the new cannabis product forms recently allowed in Canada, Neptune is progressing well to broaden its product offering into turnkey solutions for Canadian License Holders ("LHs"). The Company recently produced and shipped cannabinoid-infused powder sachets to a LH customer. In addition, Neptune, in combination with this LH customer, has completed development of cannabinoid-infused teas and commercial production is expected to start soon. These finished products are manufactured at our Sherbrooke facility and several other product forms, including but not limited to, sprays, vape pens, capsules and tinctures are expected to be produced this year.

In recent weeks, following the optimization of our extraction parameters on Neptune’s Phase I CO2 extraction equipment, extraction yields at Neptune’s Sherbrooke facility have increased by more than 10 percentage points to reach levels above 95% and allowed the team to increase process throughput.

Our Phase II equipment for ethanol extraction represents an improvement over CO2 extraction and allows us to winterize oils through an inline process, eliminating an additional manufacturing step. Management decided to upgrade the coolant system utilized in the Phase II extraction process to be consistent with the Company’s standards regarding organic processes and highest possible production standards and is looking at environmentally-friendly alternatives, such as liquid nitrogen, to maintain the intended cold temperatures throughout the manufacturing process. This decision has led to a small delay in reaching Phase II’s full extraction capacity. Future capacity utilization will be dependent on market conditions, the pace of growth of the Canadian cannabis market and the success our customers have with the rollout of their cannabis 2.0 products.

The capacity expansion at Neptune’s North Carolina SugarLeaf facility is nearing completion, as expected and on budget. With a second centrifuge installed, Neptune will be able to run multiple batches concurrently, providing more flexibility and reducing downtime. Management is putting the final touches to get the facility ready for a Good Manufacturing Practice ("GMP") pre-inspection audit which should occur in the coming weeks. A GMP certification will enable Neptune to broaden its client base. Recently, the R&D teams from both production facilities collaborated to develop an in-house technology to make a water solubility emulsion of cannabinoids. While testing is still undergoing, the initial stability tests were very positive.

Management Additions
Neptune is pleased to welcome Denis Maranda as head of production for the Sherbrooke facility. Mr. Maranda has a Bachelor’s degree in Mechanical Engineering from McGill University and a Master’s degree in Total Quality, from Concordia’ John Molson School of Business. He was previously a Plant Manager at Thyssenkrupp Aerospatiale and worked at Dart Aerospace.

Eric Dodge recently joined Neptune in the role of Senior Brand Manager, with responsibilities to oversee the growth of Forest Remedies and other Neptune’s brands. Mr. Dodge holds a Bachelor’s degree in Political Science and Economics as well as a Master of Business Administration specializing in Brand and Product Management from the University of Wisconsin – Madison. He was most recently Brand Manager – Oral Care Innovation at Tom’s of Maine, a subsidiary of Colgate-Palmolive.

To support the Company’s consumer brands, Neptune recently hired Tyler Segel as Creative Manager. Mr. Segel will be responsible for creative work on all of Neptune’s brands. He previously held the position of Creative Director for Factory North where he worked on the development of the Schmidt’s Naturals brand. Mr. Segel holds an Associate Degree in Graphic Design from Portland Community College.

Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020

On January 10, 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 6, 2020, before the U.S. financial markets open (Press release, Regeneron, JAN 10, 2020, https://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2019-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-6-2020-300984444.html [SID1234553002]). The Company will host a conference call and simultaneous webcast at 8:00 AM Eastern Time that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
To access this call, dial (800) 708-4540 (U.S.) or (847) 619-6397 (International). A link to the webcast may be accessed from the ‘Investors and Media’ page of Regeneron’s website at View Source A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer

On January 10, 2020 RhoVac AB ("RhoVac") reported, on 10th January 2020, that the company has received approval from Beligian FAMHP (Federal Agency for Medicines and Health Products) and German Federal Institute for Vaccines and Biomedicines for starting the clinical phase IIb study in prostate cancer, a multicenter study entitled RhoVac-002 ("BRaVac") (Press release, RhoVac, JAN 10, 2020, View Source [SID1234553001]). The phase IIb study is an international, multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States. RhoVac has previously received approval Denmark and Finland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BRaVac is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating if and to what extent treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent therapy measured as a limited development of PSA (Prostate Specific Antigen) in actively treated patients compared to the control group (placebo group). The Phase IIb study is an international multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States. The ambition is for all patients to be recruited by end Q3 2020. The results reporting on the primary objective of the study is expected during H2 2021. RhoVac has previously received CTA approval in Denmark and Finland.

Seneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase™ 2020

On January 10, 2020 Seneca Biopharma, Inc., (NASDAQ: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, reported that Seneca’s Executive Chairman, Ken Carter, will present at both Sachs Associates 3rd Annual Neuroscience Innovation Forum, January 12, 2020 at the Marines Memorial Club, San Francisco, and Biotech Showcase 2020, being held January 13–15, 2020 at the Hilton San Francisco Union Square (Press release, Seneca Biopharma, JAN 10, 2020, View Source;biotech-showcase-2020-300984762.html [SID1234553000]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of Seneca’s presentations are as follows:

Event: Sachs Associates 3rd Annual Neuroscience Innovation Forum
Date: Sunday, January 12 2020
Time: 4:35 p.m. PST
Room: Room Heritage
Venue: Marines Memorial Club, San Francisco, CA (United States)

Event: Biotech Showcase
Date: Tuesday, January 14 2020
Time: 10:30 a.m. PST
Room: Franciscan A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San
Francisco, CA (United States)

Sachs Associates 3rd Annual Neuroscience Innovation Forum, back for its 3rd annual edition, addresses through its conference programme the main challenges for 2020 in investment, partnering and alliance management. The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover, there are panels on innovation in neurotech covering banking, device, diagnostics and software.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.